Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a effective class of drugs in the management of type 2 diabetes mellitus. These agents mimic the actions of naturally occurring GLP-1, enhancing insulin secretion and suppressing glucagon release. Recent investigations have yielded a broad range of novel GLP-1 receptor agonists with

GLP-1 receptor agonists are emerging as a groundbreaking strategy in the management of diabetes. These innovative medications simulate the actions of naturally occurring glucagon-like peptide-1 (GLP-1), a hormone that plays a crucial role in regulating blood sugar levels. By boosting GLP-1 receptors, these drugs enhance insulin release from the pan